Bonnie Anderson is the cofounder and Chief Executive Officer of Veracyte, a molecular diagnostics company that is pioneering the field of pre-operative molecular cytology. Her career spans nearly 30 years in regulated diagnostics and life science markets where she has led both early-stage businesses, as well as mature, global enterprises. Under Ms. Anderson's leadership, Veracyte has achieved significant commercialization milestones since its formation in 2008. These include the launch of its first product - the Afirma® Thyroid FNA Analysis - designed to help reduce unnecessary surgeries in thyroid cancer diagnosis; national Medicare coverage for its gene expression test; a global co-promotion partnership with Genzyme, a Sanofi company; and publication of strong clinical validation study results in the New England Journal of Medicine. In 2011, Veracyte was named to The Wall Street Journal's "The Next Big Thing" list of the top 50 venture-backed companies.
Prior to Veracyte, Ms. Anderson provided strategic consulting services to venture capital firms and early-stage businesses following 18 years in leadership positions at Beckman Coulter, including heading the company's global cellular analysis franchise in hematology and flow cytometry, and serving as Vice President of its intrapreneurial start-up, Immunomics Operations. She graduated from Indiana University of Pennsylvania with a Bachelors of Science degree in Medical Technology and in 2012 was honored as a "Distinguished Alumni" award recipient. Additionally, in 2013, Ms. Anderson received the Silicon Valley Business Journal's "Women of Influence" award and the San Francisco Business Times' "Most Influential Women in Bay Area Business" award.